TY - JOUR T1 - Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa JF - medRxiv DO - 10.1101/2021.02.10.21251247 SP - 2021.02.10.21251247 AU - Shabir A. Madhi AU - Vicky Baillie AU - Clare L. Cutland AU - Merryn Voysey AU - Anthonet L. Koen AU - Lee Fairlie AU - Sherman D. Padayachee AU - Keertan Dheda AU - Shaun L. Barnabas AU - Qasim Ebrahim Bhorat AU - Carmen Briner AU - Gaurav Kwatra AU - NGS-SA AU - Wits-VIDA COVID team AU - Khatija Ahmed AU - Parvinder Aley AU - Sutika Bhikha AU - Jinal N. Bhiman AU - As’ad Ebrahim Bhorat AU - Jeanine du Plessis AU - Aliasgar Esmail AU - Marisa Groenewald AU - Elizea Horne AU - Shi-Hsia Hwa AU - Aylin Jose AU - Teresa Lambe AU - Matt Laubscher AU - Mookho Malahleha AU - Masebole Masenya AU - Mduduzi Masilela AU - Shakeel McKenzie AU - Kgaogelo Molapo AU - Andrew Moultrie AU - Suzette Oelofse AU - Faeezah Patel AU - Sureshnee Pillay AU - Sarah Rhead AU - Hylton Rodel AU - Lindie Rossouw AU - Carol Taoushanis AU - Houriiyah Tegally AU - Asha Thombrayil AU - Samuel van Eck AU - Constantinos Kurt Wibmer AU - Nicholas M. Durham AU - Elizabeth J Kelly AU - Tonya L Villafana AU - Sarah Gilbert AU - Andrew J Pollard AU - Tulio de Oliveira AU - Penny L. Moore AU - Alex Sigal AU - Alane Izu Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251247.abstract N2 - Background Assessing safety and efficacy of Covid-19 vaccines in different populations is essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern including the B.1.351 (501Y.V2) variant first identified in South Africa.Methods We conducted a randomized multicentre, double blinded controlled trial on safety and efficacy of ChAdOx1-nCoV19 in HIV-uninfected people in South Africa. Participants age 18 to <65 years randomized (1:1) to two doses of vaccine containing 5×1010 viral particles or placebo (0.9%NaCl) 21-35 days apart. Post 2nd-dose serum samples (n=25) were tested by pseudotyped (PSVNA) and live virus (LVNA) neutralization assays against the D614G and B.1.351 variants. Primary endpoints were safety and vaccine efficacy (VE) >14 days following second dose against laboratory confirmed symptomatic Covid-19.Results 2026 HIV-uninfected adults were enrolled between June 24th and Nov 9th, 2020; 1010 and 1011 received at least one dose of placebo or vaccine, respectively. Median age was 31 years. The B.1.351 variant showed increased resistance to vaccinee sera using the PSVNA and LVNA. In the primary endpoint analysis, 23/717 (3.2%) placebo and 19/750 (2.5%) vaccine recipients developed mild-moderate Covid-19; VE 21.9% (95%Confidence Interval: −49.9; 59.8). Of the primary endpoint cases, 39/42 (92.9%) were the B.1.351 variant; against which VE was 10.4% (95%CI: −76.8; 54.8) analyzed as a secondary objective. The incidence of serious adverse events was balanced between the vaccine and placebo groups.Conclusions A two-dose regimen of ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however, VE against severe Covid-19 is undetermined.(Funded by The Bill & Melinda Gates Foundation and South African Medical Research Council; ClinicalTrails.gov number, NCT04444674).Competing Interest StatementSAM is a member of WHO SAGE but does not participate in discussions on COVID-19 vaccines. SAM institution receive other grants related to Covid-19 research from BMGF and South African Medical Research Council. Oxford University has entered into a partnership with Astra Zeneca for further development of ChAdOx1 nCoV-19. SCG is co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine. TL is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and was a consultant to Vaccitech for an unrelated project. PMF is a consultant to Vaccitech. AJP is Chair of UK Dept. Health and Social Cares (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in discussions on COVID-19 vaccines, and is a member of the WHO SAGE. AJP is an NIHR Senior Investigator. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, NIHR or WHO. NMD, EJK and TLV are employees of Astra Zeneca. Clinical TrialNCT04444674Clinical Protocols https://www.wits.ac.za/covid19vaccine/oxford-covid-19-vaccine-trial/. Funding StatementThis report is independent research funded by the Bill & Melinda Gates Foundation (INV-017710 to SAM, INV-018944 to AS) and the South African Medical Research Council (96167). Personnel from the KD lab were supported by the South African MRC/UCT Centre for the Study of Antimicrobial Resistance (RFA-EMU-02-2017) and the EDCTP (TMA-2015SF-1043 & TMA- 1051-TESAII). AE is supported EDCTP (TMA-2015CDF-1052) We acknowledge funding from the South African Medical Research Council SHIP programme. P.L.M. is supported by the South African Research Chairs Initiative of the Department of Science and Technology and the NRF (Grant No 98341). C.K.W. is supported by Fogarty International Center of the National Institutes of Health under Award Number R21TW011454 and the FLAIR Fellowship program under award number FLR\R1\201782. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was reviewed and approved by the South African Health Products Regulatory Authority (SAHPRA, ref 20200407), ethics committees of the University of the Witwatersrand (ref 200501), Cape Town (ref 350/2020), Stellenbosch (ref M20/06/009_COVID-19) and Oxford (ref 35-20) prior to trial initiation and was registered on Clinicaltrials.gov (NCT04444674) and the Pan African Clinical Trials registry (PACTR202006922165132). All participants were fully informed about trial procedures and possible risks and signed informed consent prior to enrolment.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available by the study statistican after acceptance of the mansucript by a journal https://www.wits.ac.za/covid19vaccine/oxford-covid-19-vaccine-trial/. ER -